Literature DB >> 33573706

Potential contributors to low dose methotrexate toxicity in a patient with rheumatoid arthritis and pernicious anemia: case report.

Miguel A Jara-Palacios1, William Chun2, Nomi L Traub2.   

Abstract

BACKGROUND: Low dose methotrexate toxicity rarely occurs, but may present with severe complications, such as pancytopenia, hepatotoxicity, mucositis, and pneumonitis. Known risk factors for methotrexate toxicity include dosing errors, metabolic syndrome, hypoalbuminemia, renal dysfunction, lack of folate supplementation, and the concomitant use of drugs that interfere with methotrexate metabolism. Vitamin B12 deficiency leads to megaloblastic anemia and may cause pancytopenia, but its role in methotrexate toxicity has not been described. CASE
PRESENTATION: We present a case of a patient with rheumatoid arthritis who was admitted with febrile neutropenia, pancytopenia, and severe mucositis, likely secondary to low dose methotrexate toxicity. She had multiple factors that potentially contributed to the development of toxicity, including concurrent sulfasalazine use for rheumatoid arthritis. An evaluation of the patient's macrocytic anemia revealed pernicious anemia. The patient's illness resolved with cessation of methotrexate and sulfasalazine, leucovorin treatment and vitamin B12 repletion.
CONCLUSIONS: This case illustrates the multiple factors that may potentially contribute to low dose methotrexate toxicity and highlights the importance of testing for vitamin B12 deficiency in rheumatoid arthritis patients with macrocytic anemia. Addressing all the modifiable factors that potentially contribute to low dose methotrexate toxicity may improve outcomes.

Entities:  

Keywords:  Low dose methotrexate toxicity; Rheumatoid arthritis; Sulfasalazine; Vitamin B12 deficiency

Year:  2021        PMID: 33573706      PMCID: PMC7879510          DOI: 10.1186/s41927-020-00175-y

Source DB:  PubMed          Journal:  BMC Rheumatol        ISSN: 2520-1026


  25 in total

Review 1.  Toward a better understanding of methotrexate.

Authors:  Joel M Kremer
Journal:  Arthritis Rheum       Date:  2004-05

2.  Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.

Authors:  Vanita R Aroda; Sharon L Edelstein; Ronald B Goldberg; William C Knowler; Santica M Marcovina; Trevor J Orchard; George A Bray; David S Schade; Marinella G Temprosa; Neil H White; Jill P Crandall
Journal:  J Clin Endocrinol Metab       Date:  2016-02-22       Impact factor: 5.958

Review 3.  Vitamin B12 deficiency.

Authors:  Ralph Green; Lindsay H Allen; Anne-Lise Bjørke-Monsen; Alex Brito; Jean-Louis Guéant; Joshua W Miller; Anne M Molloy; Ebba Nexo; Sally Stabler; Ban-Hock Toh; Per Magne Ueland; Chittaranjan Yajnik
Journal:  Nat Rev Dis Primers       Date:  2017-06-29       Impact factor: 52.329

4.  Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.

Authors:  Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

5.  Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.

Authors:  Daniel H Solomon; Robert J Glynn; Elizabeth W Karlson; Fengxin Lu; Cassandra Corrigan; Josh Colls; Chang Xu; Jean MacFadyen; Medha Barbhaiya; Nancy Berliner; Paul F Dellaripa; Brendan M Everett; Aruna D Pradhan; Sarah P Hammond; Meredith Murray; Deepak A Rao; Susan Y Ritter; Anna Rutherford; Jeffrey A Sparks; Jackie Stratton; Dong H Suh; Sara K Tedeschi; Kathleen M M Vanni; Nina P Paynter; Paul M Ridker
Journal:  Ann Intern Med       Date:  2020-02-18       Impact factor: 25.391

6.  Accumulation of 5-methyltetrahydrofolate in cobalamin-deficient L1210 mouse leukemia cells.

Authors:  K Fujii; T Nagasaki; F M Huennekens
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 7.  Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.

Authors:  S Prey; C Paul
Journal:  Br J Dermatol       Date:  2008-10-20       Impact factor: 9.302

8.  Sulphasalazine associated pancytopenia may be caused by acute folate deficiency.

Authors:  E C Logan; L M Williamson; D R Ryrie
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

9.  Effect of methotrexate/vitamin B12 on DNA methylation as a potential factor in leukemia treatment-related neurotoxicity.

Authors:  Victoria J Forster; Alex McDonnell; Rachel Theobald; Jill A McKay
Journal:  Epigenomics       Date:  2017-08-15       Impact factor: 4.778

10.  Acute versus chronic methotrexate poisoning; a cross-sectional study.

Authors:  Arman Ahmadzadeh; Nasim Zamani; Hossein Hassanian-Moghaddam; Seyed Kaveh Hadeiy; Parinaz Parhizgar
Journal:  BMC Pharmacol Toxicol       Date:  2019-07-03       Impact factor: 2.483

View more
  1 in total

Review 1.  Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review.

Authors:  Nikolaos Kougkas; Athanasia Dara; Eleni Pagkopoulou; Androniki Dimitriadou; Evdokia Papadimitriou; Eugenia Avdelidou; Alexandros Garyfallos; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2022-07-18       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.